Healthcare / Drug Manufacturers - Specialty & GenericTel Aviv
$1101.00
+12.00 (+1.07%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $16.5M · quality 50.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
16/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$126M
P/E
N/A
•EV/EBITDA
488.5x
↑ROE
-12.5%
↓Gross Margin
23.1%
↓Debt/Equity
0.92
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+1.0%
FCF CAGR
-43.2%
FCF margin
1.9%
FCF / Net income
-0.32x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $301.0M · net income $-18.1M · FCF $5.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $301.0M | $301.0M | $321.7M | $321.7M | $292.4M |
| Net Income | $-18.1M | $-18.1M | $6.2M | $-6.9M | $-2.0M |
| EBITDA | $26.0M | $26.0M | $47.3M | $31.2M | $33.5M |
| EPS | — | — | 0.54 | -0.61 | -0.18 |
| Gross Margin | 23.1% | 23.1% | 22.4% | 24.9% | 26.9% |
| Operating Margin | -2.1% | -2.1% | -1.8% | 1.7% | 5.1% |
| Net Margin | -6.0% | -6.0% | 1.9% | -2.1% | -0.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.92 | 0.92 | 0.83 | 1.18 | 0.95 |
| Current Ratio | 1.53 | 1.53 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $5.8M | $5.8M | $17.8M | $16.5M | $31.5M |
| Returns | |||||
| ROE | -12.5% | -12.5% | 3.8% | -4.4% | -1.3% |
| Valuation | |||||
| P/E | — | — | 2492.59 | — | — |
| EV/EBITDA | 488.46 | 488.46 | 327.54 | 529.12 | 545.69 |
| P/B | 87.18 | 87.18 | 94.88 | 104.95 | 111.94 |
| Growth & Yield | |||||
| Revenue Growth | -6.4% | -6.4% | 0.0% | 10.0% | — |
| EPS Growth | — | — | 188.5% | -238.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-13.1%
Start / end P/E
n/dx → n/dx
EPS bridge
0.54 → n/d
Residual
-13.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.